VYVGART®
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial

VYVGART ORDER FORM

Patient Information

Name:	DOB:
Allergies:	Referral date:
◯ Change dose for weight change of greater than 10%	Patient Wt: ◯ lbs ◯ kg

Referral Status

◯ New referral	◯ Dose or Frequency Change	◯ Order renewal

Diagnosis/ICD-10 Code

◯ G70.00 Myasthenia gravis without (acute) exacerbation	◯ G70.01 Myasthenia gravis with (acute) exacerbation
◯ Generalized myasthenia gravis (gMG) anti-acetylcholine receptor (AChR) antibody positive	◯ Other:

Required Documentation

◯ This signed form by the provider ◯ Insurance and patient information	◯ Clinical progress notes ◯ Labs and tests supporting diagnosis	◯ MG-ADL score: ◯ MGFA clinical classification:

History of previous gMG therapies including dose, frequency, and duration:

Current gMG therapies:

Other:

Medication Orders

Medication	Dosing	Calculated dose	Rate of infusion	Diluent	Schedule
◯ VYVGART (efgartigimod alfa-fcab) NDC 73475-3041-5	10 mg/kg	_____ mg based on weight	Infuse over 1 hour via 0.2 micron in-line filter	0.9% sodium chloride for a total of 125 mL	Weekly x 4 weeks
◯ VYVGART (efgartigimod alfa-fcab) NDC 73475-3041-5	10 mg/kg	1200 mg for patients greater than 120 kg[a]	Infuse over 1 hour via 0.2 micron in-line filter	0.9% sodium chloride for a total of 125 mL	Weekly x 4 weeks
◯ VYVGART (efgartigimod alfa-fcab) NDC 73475-3041-5	10 mg/kg				
Date of first dose:		*# of refills (cycles):*		*Quantity (vials) per cycle:*	
Additional Instructions:					

Examples (400 mg/vial): 2 vials/infusion x 4 infusions/cycle = 8 vials/cycle or 3 vials/infusion x 4 infusions/cycle = 12 vials/cycle
For dosing calculator and other HCP resources, please visit https://vyvgarthcp.com/dosing
[a]*Maximum dose 1200 mg per infusion, for patients greater than 120 kg*

Additional Orders

◯ Monitor patients during administration and for 1 hour thereafter for clinical signs and symptoms of hypersensitivity reactions

◯ After administration of VYVGART, flush the entire line with 0.9% sodium chloride injection

Other:

Physician Information

Prescriber name:		DEA/NPI #:
Office phone:	Office fax:	Office email:

Prescriber signature:

VYVGART®
(efgartigimod alfa-fcab)
Injection for Intravenous Use
400 mg/20 mL vial

Indication

VYVGART® (efgartigimod alfa-fcab) is indicated for the treatment of generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Important Safety Information

WARNINGS AND PRECAUTIONS

Infection

VYVGART may increase the risk of infection. The most common infections observed in Study 1 were urinary tract infection (10% for VYVGART vs 5% for placebo) and respiratory tract infection (33% for VYVGART vs 29% for placebo). Patients on VYVGART vs placebo had below normal levels for white blood cell counts (12% vs 5%, respectively), lymphocyte counts (28% vs 19%, respectively), and neutrophil counts (13% vs 6%, respectively). The majority of infections and hematologic abnormalities were mild to moderate in severity. Delay VYVGART administration in patients with an active infection until the infection is resolved; monitor for clinical signs and symptoms of infections. If serious infection occurs, administer appropriate treatment and consider withholding VYVGART until the infection has resolved.

Immunization

Immunization with vaccines during VYVGART treatment has not been studied; the safety with live or live-attenuated vaccines and the response to immunization with any vaccine are unknown. Because VYVGART causes a reduction in immunoglobulin G (IgG) levels, vaccination with live-attenuated or live vaccines is not recommended during VYVGART treatment. Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of a new treatment cycle with VYVGART.

Hypersensitivity Reactions

Hypersensitivity reactions, including rash, angioedema, and dyspnea, were observed with VYVGART. In clinical trials, hypersensitivity reactions were mild or moderate, occurred within 1 hour to 3 weeks of administration, and did not lead to treatment discontinuation. Monitor patients during administration and for 1 hour thereafter for clinical signs and symptoms of hypersensitivity reactions. If a hypersensitivity reaction occurs during administration, discontinue VYVGART infusion and institute appropriate supportive measures if needed.

Adverse Reactions

The most common (≥10%) adverse reactions with VYVGART were respiratory tract infection, headache, and urinary tract infection.

USE IN SPECIFIC POPULATIONS

Pregnancy

As VYVGART is expected to reduce maternal IgG antibody levels, reduction in passive protection to the newborn is anticipated. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to infants exposed to VYVGART in utero.

Lactation

There is no information regarding the presence of VYVGART in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VYVGART and any potential adverse effects on the breastfed infant from VYVGART or from the underlying maternal condition.

Please see full Prescribing Information.

You may report side effects to the US Food and Drug Administration by visiting http://www.fda.gov/medwatch or calling 1-800-FDA-1088. You may also report side effects to argenx US, Inc, at 1-833-argx411 (1-833-274-9411).

Additional Resources

If you have additional questions about **VYVGART**, please contact **My VYVGART Path** at 1-833-MY-PATH-1 (1-833-697-2841) where you can be connected to the appropriate resource.

You can access downloadable resources by visiting VYVGARTHCP.com.

My VYVGART® Path

argenx